Ruxolitinib as front-line therapy in graft versus host disease: Efficacy and safety in children

Background: Ruxolinitib has been used as an effective salvage agent in steroid refractory acute and chronic graft versus host disease (GVHD). We aimed to analyze data on ruxolitinib as front-line therapy in children. Patients and methods: We included children up to 18 years of age who underwent hema...

Full description

Bibliographic Details

Published in:	Pediatric Hematology Oncology Journal
Main Authors:	Revathi Raj, Venkateswaran Vellaichamy Swaminathan, Satishkumar Meena, Harika Varla, Rumesh Chandar, Balasubramaniam Ramakrishnan, Ramya Uppuluri
Format:	Article
Language:	English
Published:	Elsevier 2021-12-01
Subjects:	Ruxolitinib Children Graft versus host disease Mortality Infections Transplant-related mortality
Online Access:	http://www.sciencedirect.com/science/article/pii/S2468124521002527